Bristol tax reporting (correction)
Executive Summary
Bristol-Myers Squibb's incoming tax reporting controls remain a "reportable condition," according to the company's auditors, PricewaterhouseCoopers. In a story on Bristol's latest earnings restatement, "The Pink Sheet" incorrectly reported that the tax controls are considered a "material weakness." Bristol has resolved both "material weaknesses" identified by PwC a year ago (1"The Pink Sheet" March 22, 2004, p. 24)...
You may also be interested in...
Bristol Re-Restates: Income Taxes, “Grants” May Be Ongoing Issues
Bristol-Myers Squibb still has work to do to resolve its income tax reporting processes, the company acknowledged in a 10-K filed with the Securities & Exchange Commission March 15
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.